- Home
- CVKD vs CALC Comparison
CVKD vs CALC Comparison
Compare CVKD & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- CALC
- Stock Information
- Founded
- CVKD 2022
- CALC 2011
- Country
- CVKD United States
- CALC United States
- Employees
- CVKD N/A
- CALC N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- CALC Health Care
- Exchange
- CVKD Nasdaq
- CALC Nasdaq
- Market Cap
- CVKD 34.2M
- CALC 36.0M
- IPO Year
- CVKD 2023
- CALC N/A
- Fundamental
- Price
- CVKD $17.77
- CALC $1.97
- Analyst Decision
- CVKD Strong Buy
- CALC Strong Buy
- Analyst Count
- CVKD 1
- CALC 4
- Target Price
- CVKD $32.00
- CALC $17.25
- AVG Volume (30 Days)
- CVKD 44.3K
- CALC 32.6K
- Earning Date
- CVKD 05-08-2025
- CALC 03-27-2025
- Dividend Yield
- CVKD N/A
- CALC N/A
- EPS Growth
- CVKD N/A
- CALC N/A
- EPS
- CVKD N/A
- CALC N/A
- Revenue
- CVKD N/A
- CALC N/A
- Revenue This Year
- CVKD N/A
- CALC N/A
- Revenue Next Year
- CVKD N/A
- CALC N/A
- P/E Ratio
- CVKD N/A
- CALC N/A
- Revenue Growth
- CVKD N/A
- CALC N/A
- 52 Week Low
- CVKD $5.40
- CALC $1.86
- 52 Week High
- CVKD $22.90
- CALC $6.27
- Technical
- Relative Strength Index (RSI)
- CVKD 49.27
- CALC 34.55
- Support Level
- CVKD $14.64
- CALC $2.02
- Resistance Level
- CVKD $17.58
- CALC $2.35
- Average True Range (ATR)
- CVKD 1.86
- CALC 0.23
- MACD
- CVKD -0.29
- CALC 0.00
- Stochastic Oscillator
- CVKD 39.10
- CALC 26.35
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.